## Mikihito Nakamori

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11716117/publications.pdf

Version: 2024-02-01

218677 276875 2,130 90 26 41 citations h-index g-index papers 91 91 91 2503 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Impact of postoperative complications on survival outcomes in patients with gastric cancer: exploratory analysis of a randomized controlled JCOG1001 trial. Gastric Cancer, 2021, 24, 214-223.	5.3	32
2	Phase 1 Study of Combined Chemotherapy of Nab-Paclitaxel, S-1, and Oxaliplatin for Gastric Cancer with Peritoneal Metastasis (NSOX Study). Oncology, 2021, 99, 57-61.	1.9	7
3	Oncolytic virotherapy with SOCS3 enhances viral replicative potency and oncolysis for gastric cancer. Oncotarget, 2021, 12, 344-354.	1.8	7
4	Oncolytic virotherapy with human telomerase reverse transcriptase promoter regulation enhances cytotoxic effects against gastric cancer. Oncology Letters, 2021, 21, 490.	1.8	6
5	Short-term Outcomes of Robotic Gastrectomy vs Laparoscopic Gastrectomy for Patients With Gastric Cancer. JAMA Surgery, 2021, 156, 954.	4.3	87
6	Endoscopic submucosal tunnel dissection versus conventional endoscopic submucosal dissection for early gastric cancers: outcomes of 799 consecutive cases in a single institution. Surgical Endoscopy and Other Interventional Techniques, 2020, 34, 5625-5631.	2.4	11
7	Anticancer effects of chemokine-directed antigen delivery to a cross-presenting dendritic cell subset with immune checkpoint blockade. British Journal of Cancer, 2020, 122, 1185-1193.	6.4	14
8	Postoperative atrial fibrillation does not impact on overall survival after esophagectomy in patients with thoracic esophageal cancer: results from a randomized, double-blind, placebo-controlled trial. Oncotarget, 2020, 11, 2414-2423.	1.8	4
9	Conversion surgery for advancedgastric cancer with peritoneal metastasis Journal of Clinical Oncology, 2020, 38, 450-450.	1.6	O
10	Surrogate indicators of survival in patients who received neoadjuvant chemotherapy for type 4 and large type 3 gastric cancer in JCOG0501 Journal of Clinical Oncology, 2020, 38, 381-381.	1.6	1
11	Robotic distal gastrectomy with D2 lymphadenectomy for gastric cancer in a patient with situs inversus totalis. Surgical Oncology, 2019, 30, 98-99.	1.6	9
12	Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial. The Lancet Gastroenterology and Hepatology, 2019, 4, 501-510.	8.1	88
13	Loss of CEACAM1 is associated with poor prognosis and peritoneal dissemination of patients with gastric cancer. Scientific Reports, 2019, 9, 12702.	3.3	21
14	Triangulating stapling vs functional end-to-end stapling for cervical esophagogastric anastomosis after esophagectomy for thoracic esophageal cancer: study protocol for a randomized controlled trial. Trials, 2019, 20, 83.	1.6	4
15	Robotic radical lymphadenectomy without touching the pancreas during gastrectomy for gastric cancer. Medicine (United States), 2019, 98, e15091.	1.0	14
16	Laparoscopic Billroth I Gastroduodenostomy in Robotic Distal Gastrectomy for Gastric Cancers: Fusion Surgery. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2019, 29, 520-523.	0.8	3
17	Conversion Surgery for Gastric Cancer with Peritoneal Metastasis Based on the Diagnosis of Second-Look Staging Laparoscopy. Journal of Gastrointestinal Surgery, 2019, 23, 1758-1766.	1.7	29
18	Triplet chemotherapy with docetaxel, cisplatin and S-1 for unresectable advanced squamous cell carcinoma of the esophagus: phase I/II trial results. Oncotarget, 2019, 10, 847-855.	1.8	8

#	Article	IF	Citations
19	Prevention of Internal Hernia During Robotic Total Gastrectomy for Gastric Cancer. Journal of Gastrointestinal Surgery, 2018, 22, 934.	1.7	4
20	Fundoplication with 180-Degree Wrap During Esophagogastrostomy After Robotic Proximal Gastrectomy for Early Gastric Cancer. Journal of Gastrointestinal Surgery, 2018, 22, 1475-1476.	1.7	5
21	Laparoscopic and Endoscopic Cooperative Surgery Versus Endoscopic Submucosal Dissection for the Treatment of Low-Risk Tumors of the Duodenum. Journal of Gastrointestinal Surgery, 2018, 22, 935-940.	1.7	21
22	Usefulness of indocyanine green fluorescence imaging: <scp>A</scp> case of laparoscopic distal gastrectomy after distal pancreatectomy with splenectomy. Asian Journal of Endoscopic Surgery, 2018, 11, 252-255.	0.9	7
23	Cancer Vaccine Therapy Using Carcinoembryonic Antigen - expressing Dendritic Cells generated from Induced Pluripotent Stem Cells. Scientific Reports, 2018, 8, 4569.	3.3	23
24	Long-term outcomes of laparoscopy-assisted distal gastrectomy with suprapancreatic nodal dissection for clinical stage I gastric cancer: a multicenter phase II trial (JCOG0703). Gastric Cancer, 2018, 21, 155-161.	5.3	61
25	Laparoscopic and endoscopic cooperative surgery is a feasible treatment procedure for intraluminal gastric gastrointestinal stromal tumors compared to endoscopic intragastric surgery. Surgical Endoscopy and Other Interventional Techniques, 2018, 32, 351-357.	2.4	18
26	Endoscopic treatment of esophageal fistulas after esophagectomy with injection of an alpha-cyanoacrylate monomer: a phase II study. Endoscopy International Open, 2018, 06, E1093-E1099.	1.8	12
27	RA02.06: PREVENTION OF ATRIAL FIBRILLATION AND POSTOPERATIVE COMPLICATIONS USING LANDIOLOL HYDROCHLORIDE AFTER ESOPHAGECTOMY FOR ESOPHAGEAL CANCER. Ecological Management and Restoration, 2018, 31, 21-21.	0.4	0
28	PS01.199: A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL OF CIRCULAR STAPLING VERSUS TRIANGULATING STAPLING ESOPHAGOGASTRIC ANASTOMOSIS FOR ESOPHAGEAL CANCER. Ecological Management and Restoration, 2018, 31, 106-106.	0.4	1
29	Reinforced Stapling Technique for Reconstruction After Laparoscopic Distal Gastrectomy. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2018, 28, 334-336.	0.8	10
30	Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and S-1 for Resectable Advanced Esophageal Cancer. Anticancer Research, 2018, 38, 5267-5273.	1.1	20
31	Phase I/II Trial of Chemotherapy with Docetaxel, Cisplatin, and S-1 for Unresectable Advanced Squamous Cell Carcinoma of the Esophagus. Oncology, 2018, 95, 116-120.	1.9	2
32	Robotic versus laparoscopic gastrectomy with lymph node dissection for gastric cancer: study protocol for a randomized controlled trial. Trials, 2018, 19, 409.	1.6	20
33	A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002. Gastric Cancer, 2017, 20, 322-331.	5.3	94
34	Expression of BRCA1, a factor closely associated with relapse-free survival, in patients who underwent neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil for squamous cell carcinoma of the esophagus. Surgery Today, 2017, 47, 65-73.	1.5	9
35	Laparoscopic Gastrojejunostomy for Patients with Unresectable Gastric Cancer with Gastric Outlet Obstruction. Journal of Gastrointestinal Surgery, 2017, 21, 1220-1225.	1.7	24
36	Circular stapling versus triangulating stapling for the cervical esophagogastric anastomosis after esophagectomy in patients with thoracic esophageal cancer: A prospective, randomized, controlled trial. Surgery, 2017, 162, 131-138.	1.9	41

#	Article	IF	CITATIONS
37	Internal Hernia After Laparoscopic Total Gastrectomy for Gastric Cancer. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2017, 27, 470-473.	0.8	20
38	Randomized phase II study of daily and alternate-day administration of S-1 for advanced gastric cancer (JFMC43-1003). International Journal of Clinical Oncology, 2017, 22, 1052-1059.	2.2	5
39	Long-term Survival of Patients With Endoscopic Submucosal Dissection for Remnant Gastric Cancers. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2016, 26, 78-81.	0.8	5
40	Feasibility of Endoscopic Submucosal Dissection for Submucosal-invasive Gastric Cancer and the Predictors of Residual or Recurrent Cancer. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2016, 26, 401-405.	0.8	4
41	Successful treatment of chylothorax after esophagectomy using octreotide and etilefrine. Esophagus, 2016, 13, 306-310.	1.9	5
42	The effects of rikkunshito on body weight loss after esophagectomy. Journal of Surgical Research, 2016, 204, 130-138.	1.6	13
43	Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus. Anticancer Research, 2016, 36, 829-34.	1.1	10
44	Laparoscopic Combined Resection of Synchronous Gastric and Colorectal Cancer. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2015, 25, 43-46.	0.8	7
45	Long-term survival results of laparoscopy-assisted distal gastrectomy with suprapancreatic nodal dissection for clinical stage I gastric cancer: A multicenter phase II trial (JCOG 0703) Journal of Clinical Oncology, 2015, 33, 113-113.	1.6	1
46	A phase I/II study of divided-dose docetaxel, cisplatin, and fluorouracil (DCF) for patients with recurrent or metastatic squamous cell carcinoma of the esophagus Journal of Clinical Oncology, 2015, 33, 132-132.	1.6	0
47	A Case of Chylothorax Appeared after Surgery for Esophageal Cancer Cured by Administration of Octreotide / Etilefrine and Injection of OK-432 into the Pleural Cavity. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2014, 75, 1547-1550.	0.0	6
48	Endoscopic submucosal dissection for gastric tumors in various types of remnant stomach. Endoscopy, 2014, 46, 645-649.	1.8	25
49	Successful treatment of esophageal fistulas with endoscopic injection of alpha-cyanoacrylate monomer. Endoscopy, 2014, 46, E62-E63.	1.8	8
50	Antitumor immune response of dendritic cells (DCs) expressing tumorâ€associated antigens derived from induced pluripotent stem cells: In comparison to bone marrowâ€derived DCs. International Journal of Cancer, 2014, 134, 332-341.	5.1	18
51	Complications of Endoscopic Submucosal Dissection for Gastric Noninvasive Neoplasia. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2014, 24, 370-374.	0.8	24
52	Reconstruction after proximal gastrectomy for early gastric cancer in the upper third of the stomach: An analysis of our 13-year experience. Surgery, 2014, 156, 57-63.	1.9	91
53	Atrial fibrillation after esophageal cancer surgery: an analysis of 207 consecutive patients. Surgery Today, 2014, 44, 839-847.	1.5	50
54	Clinical benefits of thoracoscopic esophagectomy in the prone position for esophageal cancer. Surgery Today, 2014, 44, 1708-1715.	1.5	22

#	Article	IF	CITATIONS
55	Is Preoperative Colonoscopy Necessary for Patients Undergoing Gastric Cancer Surgery?. Annals of Surgical Oncology, 2014, 21, 379-384.	1.5	6
56	Prognostic significance of IL-17 mRNA expression in peritoneal lavage in gastric cancer patients who underwent curative resection. Oncology Reports, 2014, 31, 605-612.	2.6	23
57	An armed oncolytic herpes simplex virus expressing thrombospondinâ€1 has an enhanced <i>in vivo</i> antitumor effect against human gastric cancer. International Journal of Cancer, 2013, 132, 485-494.	5.1	39
58	Inhibition of IL-17A in Tumor Microenvironment Augments Cytotoxicity of Tumor-Infiltrating Lymphocytes in Tumor-Bearing Mice. PLoS ONE, 2013, 8, e53131.	2.5	49
59	The evaluation of surgical treatment for gastric cancer patients with noncurative resection. Langenbeck's Archives of Surgery, 2012, 397, 959-966.	1.9	4
60	The impact of abdominal shape index of patients on laparoscopy-assisted distal gastrectomy for early gastric cancer. Langenbeck's Archives of Surgery, 2012, 397, 437-445.	1.9	19
61	Dendritic cells adenovirally-transduced with full-length mesothelin cDNA elicit mesothelin-specific cytotoxicity against pancreatic cancer cell lines in vitro. Cancer Letters, 2011, 305, 32-39.	7.2	27
62	Optimal Period for the Prophylactic Administration of Neutrophil Elastase Inhibitor for Patients with Esophageal Cancer Undergoing Esophagectomy. World Journal of Surgery, 2011, 35, 1573-1579.	1.6	13
63	Clinicopathological Characteristics of Remnant Gastric Cancer After a Distal Gastrectomy. Journal of Gastrointestinal Surgery, 2010, 14, 277-281.	1.7	36
64	Influence of Overweight on Patients With Gastric Cancer After Undergoing Curative Gastrectomy. Archives of Surgery, 2009, 144, 351.	2.2	73
65	Skeletal muscle metastasis from esophageal cancer: a report of two cases and a review of the literature. Esophagus, 2009, 6, 117-121.	1.9	5
66	Association of Allogeneic Blood Transfusions and Long-Term Survival of Patients with Gastric Cancer after Curative Gastrectomy. Journal of Gastrointestinal Surgery, 2009, 13, 1821-1830.	1.7	75
67	Evaluation of Double Tract Reconstruction After Total Gastrectomy in Patients with Gastric Cancer: Prospective Randomized Controlled Trial. World Journal of Surgery, 2009, 33, 1882-1888.	1.6	29
68	Optimal dose of preoperative enteral immunonutrition for patients with esophageal cancer. Surgery Today, 2009, 39, 855-860.	1.5	19
69	An analysis of the factors contributing to a reduction in the incidence of pulmonary complications following an esophagectomy for esophageal cancer. Langenbeck's Archives of Surgery, 2008, 393, 127-133.	1.9	64
70	Tumor vaccine therapy against recrudescent tumor using dendritic cells simultaneously transfected with tumor RNA and granulocyte macrophage colony-stimulating factor RNA. Cancer Science, 2008, 99, 407-413.	3.9	20
71	Laparoscopic resection for gastrointestinal stromal tumors of the stomach. American Journal of Surgery, 2008, 196, 425-429.	1.8	58
72	Antitumor effects of two newly constructed oncolytic herpes simplex viruses against renal cell carcinoma. International Journal of Oncology, 2007, 30, 1561.	3.3	6

#	Article	IF	CITATIONS
73	Benefits of gene transduction of granulocyte macrophage colony-stimulating factor in cancer vaccine using genetically modified dendritic cells. International Journal of Oncology, 2007, , .	3.3	3
74	Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice. International Journal of Cancer, 2007, 120, 585-593.	5.1	54
75	Surgical Management of Small Gastrointestinal Stromal Tumors of the Stomach. World Journal of Surgery, 2006, 30, 28-35.	1.6	77
76	Dendritic Cells Transduced with Tumor-Associated Antigen Gene Elicit Potent Therapeutic Antitumor Immunity: Comparison with Immunodominant Peptide-Pulsed DCs. Oncology, 2005, 68, 163-170.	1.9	38
77	Destruction of nonimmunogenic mammary tumor cells by a fusogenic oncolytic herpes simplex virus induces potent antitumor immunity. Molecular Therapy, 2004, 9, 658-665.	8.2	53
78	Potent antitumor activity after systemic delivery of a doubly fusogenic oncolytic herpes simplex virus against metastatic prostate cancer. Prostate, 2004, 60, 53-60.	2.3	43
79	Adenoviral-mediated Gene transduction of the hepatocyte growth factor (HGF) antagonist, NK4, suppresses peritoneal metastases of gastric cancer in nude mice. European Journal of Cancer, 2004, 40, 2135-2142.	2.8	32
80	Clinical benefit of chemosensitivity test for patients with regional lymph node-positive esophageal squamous cell carcinoma. Journal of Surgical Oncology, 2003, 84, 10-16.	1.7	6
81	Improvement of carcinoembryonic antigen-specific prodrug gene therapy for experimental colon cancer. Surgery, 2003, 133, 309-317.	1.9	20
82	Intensification of antitumor effect by T helper 1-dominant adoptive immunogene therapy for advanced orthotopic colon cancer. Clinical Cancer Research, 2003, 9, 2357-65.	7.0	23
83	Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanisms. Clinical Cancer Research, 2003, 9, 2727-33.	7.0	49
84	Locoregional Chemotherapy for Patients with Pancreatic Cancer Intra-arterial Adjuvant Chemotherapy After Pancreatectomy with Portal Vein Resection. Pancreas, 2002, 25, 366-372.	1.1	41
85	Dose of Adenoviral Vectors Expressing Interleukin-2 Plays an Important Role in Combined Gene Therapy with Cytosine Deaminase/5-Fluorocytosine: Preclinical Consideration. Japanese Journal of Cancer Research, 2002, 93, 706-715.	1.7	6
86	Dendritic cells genetically engineered to simultaneously express endogenous tumor antigen and granulocyte macrophage colony-stimulating factor elicit potent therapeutic antitumor immunity. Clinical Cancer Research, 2002, 8, 2742-9.	7.0	38
87	Antitumor Effects of Interleukin-2 Gene-modified Fibroblasts in an Orthotopic Colon Cancer Model. Japanese Journal of Cancer Research, 1999, 90, 1000-1006.	1.7	8
88	P-glycoprotein-expressing tumor cells are resistance to anticancer drugs in human gastrointestinal cancer. Surgery Today, 1999, 29, 591-596.	1.5	10
89	Clinical evaluation of chemosensitivity testing for patients with colorectal cancer using MTT assay. Diseases of the Colon and Rectum, 1996, 39, 416-422.	1.3	29
90	Streptococcal preparation OK-432 promotes the capacity of dendritic cells (DCs) to prime carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocyte responses induced with genetically modified DCs that express CEA. International Journal of Oncology, 0, , .	3.3	4